[Form 4] SpyGlass Pharma, Inc. Insider Trading Activity
Rhea-AI Filing Summary
SpyGlass Pharma insider entity Vensana Capital I, L.P., through its affiliated general partner, reported multiple transactions in connection with the company’s initial public offering. On February 9, 2026, its holdings of Series B, Series C‑1, Series C‑2 and Series D preferred stock automatically converted into common stock on a one‑for‑5.7329 basis immediately before the IPO, resulting in indirect ownership of 3,145,619 common shares. On the same date, the entity also purchased 165,000 common shares at $16 per share, bringing its total indirect common stock position to 3,310,619 shares, which are held by Vensana Capital I, L.P. The filing notes that Vensana Capital I GP, LLC and its managing directors, including board member Kirk Nielsen and Peter Justin Klein, may be deemed to share voting and investment power, but they disclaim beneficial ownership except to the extent of their pecuniary interests.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Preferred Stock | 9,689,922 | $0.00 | -- |
| Conversion | Series C-1 Preferred Stock | 3,142,015 | $0.00 | -- |
| Conversion | Series C-2 Preferred Stock | 3,142,015 | $0.00 | -- |
| Conversion | Series D Preferred Stock | 2,059,573 | $0.00 | -- |
| Conversion | Common Stock | 1,690,230 | $0.00 | -- |
| Conversion | Common Stock | 548,067 | $0.00 | -- |
| Conversion | Common Stock | 548,067 | $0.00 | -- |
| Conversion | Common Stock | 359,255 | $0.00 | -- |
| Purchase | Common Stock | 165,000 | $16.00 | $2.64M |
Footnotes (1)
- Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
